Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in-vitro evaluation

Figures & data

Table 1 Polymer–drug composition of nanoparticles

Batch nr	Tamoxifen citrate (mg)	PLGA (mg)
BS-1	5	238
BS-2	5	240
BS-3	10	512

Table 2 Percentage yield and loading efficiency of the experimental formulations

Formulation code	Speed of homogenization (rpm)	Speed of centrifugation for separation (rpm)	Yield (%)	Loading efficiency (%) (mean ± SD, n = 3)	Polydispersity index (PDI)
BS-1LS	16000	5000	44.07	33.16 ± 0.16	0.02
BS-2LS	16000	5000	44.86	36.35 ± 0.87	0.03
BS-3LS	16000	5000	88.86	71.98 ± 1.58	0.02
BS-1HS	16000	14000	21.17	18.60 ± 0.16	0.03
BS-2HS	16000	14000	25.56	20.84 ± 0.17	0.03
BS-3HS	16000	14000	58.19	50.75 ± 0.85	0.04

Figure 1 FTIR spectra of A) tamoxifen citrate; B) PLGA; C) mixture of drug and excipients; D) freshly prepared nanoparticles in the formulation (BS-3HS).

Figure 2 Scanning electron microscopy of PLGA nanoparticles A) BS-1LS; B) BS-1HS; C) BS-2LS; D) BS-2HS; E) BS-3LS; F) BS-3HS.

Figure 3 Particle size distribution pattern of experimental nanoparticles A) BS-3LS; B) BS-3HS.

Figure 4 In vitro drug release profile in phosphate buffer solution at Ph 7.4.

Figure 5 FTIR spectra of experimental nanoparticles A) freshly prepared nanoparticles; B) stored at 2–8°C for 90 days; C) stored at 25°C for 90 days; D) stored at 45°C for 90 days; E) stored at 60°C for 90 days.